Match!
Chyongchiou J. Lin
University of Pittsburgh
PediatricsVaccinationInfluenza vaccineFamily medicineMedicine
34Publications
14H-index
539Citations
What is this?
Publications 36
Newest
#1Angela R. Wateska (University of Pittsburgh)H-Index: 16
#2Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
Last. Kenneth J. Smith (University of Pittsburgh)H-Index: 27
view all 7 authors...
BACKGROUND/OBJECTIVES: Recently revised vaccination recommendations for US adults, aged 65 years and older, include both 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13), with PCV13 now recommended for immunocompetent older people based on shared decision making. The public health impact and cost-effectiveness of this recommendation or of pneumococcal vaccine uptake improvement interventions are unclear. DESIGN: Markov decision analysis....
Source
#1Angela R. Wateska (University of Pittsburgh)H-Index: 16
#2Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
Last. Kenneth J. Smith (University of Pittsburgh)H-Index: 27
view all 7 authors...
In US adults aged < 65 years, pneumococcal vaccination is recommended when high-risk conditions are present, but vaccine uptake is low. Additionally, there are race-based differences in illness risk and vaccination rates. The cost-effectiveness of programs to improve vaccine uptake or of alternative vaccination policies to increase protection is unclear. A decision analysis compared, in US black and general population cohorts aged 50 years, the public health impact and cost-effectiveness of pneu...
Source
#1Angela R. Wateska (University of Pittsburgh)H-Index: 16
#2Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
Last. Kenneth J. Smith (University of Pittsburgh)H-Index: 27
view all 7 authors...
Introduction Recommending both the conjugate and polysaccharide pneumococcal vaccines to all U.S. seniors may have little public health impact and be economically unreasonable. Public health impact and cost-effectiveness of using both vaccines in all adults aged ≥65 years were estimated compared with an alternative strategy (omitting pneumococcal conjugate vaccine in the nonimmunocompromised) and with the newly revised recommendation (giving or omitting conjugate vaccine based on patient–physici...
Source
#1Angela R. Wateska (University of Pittsburgh)H-Index: 16
#2Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
Last. Kenneth J. Smith (University of Pittsburgh)H-Index: 27
view all 7 authors...
ABSTRACTIn the U.S., pneumococcal polysaccharide vaccine (PPSV23) uptake among high-risk adults aged <65 years is consistently low and improvement is needed. One barrier to improved vaccine coverage is the complexity of the adult vaccination schedule. This exploratory analysis compared the cost-effectiveness of strategies to increase pneumococcal vaccine uptake in high-risk adults aged 50–64 years. We used a Markov model to compare strategies for non-immunocompromised 50–64 year olds: 1) current...
Source
#1Angela R. Wateska (University of Pittsburgh)H-Index: 16
#2Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
Last. Kenneth J. Smith (University of Pittsburgh)H-Index: 27
view all 7 authors...
Abstract Background Changing pneumococcal disease epidemiology due to childhood vaccination has prompted re-examination of US adult pneumococcal vaccination policies, as have considerations of greater pneumococcal disease incidence and higher prevalence of conditions that increase risk in underserved minority populations. Prior analyses suggest routine pneumococcal vaccination at age 50 could be considered, which could disproportionately benefit underserved populations. Methods A Markov cohort m...
1 CitationsSource
#1Angela R. Wateska (University of Pittsburgh)H-Index: 16
#2Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
Last. Chyongchiou J. Lin (University of Pittsburgh)H-Index: 14
view all 5 authors...
Adults aged 18–64 years with comorbid conditions are at high risk for complications of certain vaccine-preventable diseases, including influenza and pneumococcal disease. The 4 Pillars™ Practice Transformation Program (4 Pillars Program) increases uptake of pneumococcal polysaccharide vaccine, influenza vaccine and tetanus-diphtheria-acellular pertussis vaccine by 5–10% among adults with high-risk medical conditions, but its cost-effectiveness is unknown. A decision tree model estimated the cost...
3 CitationsSource
#1Kelly Stefano Cole (University of Pittsburgh)H-Index: 22
#2Judith M. Martin (University of Pittsburgh)H-Index: 19
Last. Richard K. Zimmerman (University of Pittsburgh)H-Index: 35
view all 7 authors...
• Selected RNA sequencing was studied before and after LAIV and IIV administration in children.
3 CitationsSource
#1Kenneth J. Smith (University of Pittsburgh)H-Index: 27
#2Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
Last. Richard K. Zimmerman (University of Pittsburgh)H-Index: 35
view all 4 authors...
ABSTRACTThe cost-effectiveness of the 4 Pillars™ Practice Transformation Program to improve vaccination rates in adults <65-years-old is unknown. Two vaccines, influenza and Tdap (tetanus, diphtheria, acellular pertussis), were targeted for this age group. Cost-effectiveness of the intervention compared with control, with a primary outcome of cost per quality adjusted life year (QALY) gained, was estimated from societal and third party payer perspectives over a 10-year time horizon using a decis...
1 CitationsSource
#1Chyongchiou J. Lin (University of Pittsburgh)H-Index: 14
#2Judith M. Martin (University of Pittsburgh)H-Index: 19
Last. Mary Patricia Nowalk (University of Pittsburgh)H-Index: 36
view all 10 authors...
ABSTRACTBackground: Vitamin D is an immunomodulating hormone, which has been associated with susceptibility to infectious diseases.Methods: Serum vitamin D levels in 135 children ages 3–17 y were measured at baseline and hemagglutinin influenza antibody titers were measured pre- and 21 d post influenza vaccination with live attenuated influenza vaccine (LAIV) or inactivated influenza vaccine (IIV). Height and weight were derived from the electronic medical record and were used to calculate body ...
5 CitationsSource
#1Kenneth J. Smith (University of Pittsburgh)H-Index: 27
#2Richard K. Zimmerman (University of Pittsburgh)H-Index: 4
Last. Chyongchiou J. Lin (University of Pittsburgh)H-Index: 14
view all 4 authors...
Objectives To estimate the cost-effectiveness of an intervention to increase pneumococcal, influenza, and pertussis-containing vaccine uptake in adults aged 65 and older in primary care practices. Design Markov decision analysis model, comparing the cost-effectiveness of the 4 Pillars Practice Transformation Program with no intervention. Setting Diverse primary care practices in two U.S. cities. Participants Clinical trial participants aged 65 and older. Measurements Quality-adjusted life years ...
4 CitationsSource
1234